IR-501: IMNR completed enrollment of a 90-patient Phase II trial

The Immune Response Corp. (IMNR) Carlsbad, Calif. Product: IR-501, three peptide combination therapy Indication: Rheumatoid arthritis Status: IMNR completed enrollment of a 90-patient Phase II trial w...